255 related articles for article (PubMed ID: 29712663)
1. A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole.
van Iersel MLPS; Rossenu S; de Greef R; Waskin H
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712663
[TBL] [Abstract][Full Text] [Related]
2. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.
Krishna G; Ma L; Martinho M; Preston RA; O'Mara E
J Antimicrob Chemother; 2012 Nov; 67(11):2725-30. PubMed ID: 22833639
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A; Kartsonis N; Van Iersel M; Connelly N; Waskin H
J Antimicrob Chemother; 2016 Mar; 71(3):718-26. PubMed ID: 26612870
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.
Petitcollin A; Boglione-Kerrien C; Tron C; Nimubona S; Lalanne S; Lemaitre F; Bellissant E; Verdier MC
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848009
[TBL] [Abstract][Full Text] [Related]
5. Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.
Kersemaekers WM; Dogterom P; Xu J; Marcantonio EE; de Greef R; Waskin H; van Iersel ML
Antimicrob Agents Chemother; 2015; 59(6):3385-9. PubMed ID: 25824210
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
[TBL] [Abstract][Full Text] [Related]
7. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.
Duarte RF; López-Jiménez J; Cornely OA; Laverdiere M; Helfgott D; Haider S; Chandrasekar P; Langston A; Perfect J; Ma L; van Iersel ML; Connelly N; Kartsonis N; Waskin H
Antimicrob Agents Chemother; 2014 Oct; 58(10):5758-65. PubMed ID: 25049247
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.
Durani U; Tosh PK; Barreto JN; Estes LL; Jannetto PJ; Tande AJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4914-8. PubMed ID: 26055378
[TBL] [Abstract][Full Text] [Related]
9. An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers.
Chen L; Krekels EHJ; Heijnen AR; Knibbe CAJ; Brüggemann RJ
Drugs; 2023 Jan; 83(1):75-86. PubMed ID: 36607589
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients.
Peña-Lorenzo D; Rebollo N; Sánchez-Hernández JG; Zarzuelo-Castañeda A; Vázquez-López L; Otero MJ; Pérez-Blanco JS
Eur J Pharm Sci; 2022 Jan; 168():106049. PubMed ID: 34699939
[TBL] [Abstract][Full Text] [Related]
11. Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.
Leclerc E; Combarel D; Uzunov M; Leblond V; Funck-Brentano C; Zahr N
Sci Rep; 2018 Jan; 8(1):1681. PubMed ID: 29374234
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
Liebenstein TK; Widmer KM; Fallon MJ
J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
[TBL] [Abstract][Full Text] [Related]
13. Posaconazole pharmacokinetics after administration of an intravenous solution, oral suspension, and delayed-release tablet to dogs.
Kendall J; Papich MG
Am J Vet Res; 2015 May; 76(5):454-9. PubMed ID: 25909378
[TBL] [Abstract][Full Text] [Related]
14. A population pharmacokinetic model for posaconazole intravenous solution and oral powder for suspension formulations in pediatric patients with neutropenia.
Winchell G; de Greef R; Ouerdani A; Fauchet F; Wrishko RE; Mangin E; Bruno C; Waskin H
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0119723. PubMed ID: 38376229
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
[TBL] [Abstract][Full Text] [Related]
16. Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole.
Guarascio AJ; Slain D
Pharmacotherapy; 2015 Feb; 35(2):208-19. PubMed ID: 25644669
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.
Liu K; Wu D; Li J; Chen H; Ning H; Zhao T; Dai H; Chen L; Mangin E; Winchell GA; Waskin H; Jiang J; Qiu Y; Zhao XM
Adv Ther; 2020 May; 37(5):2493-2506. PubMed ID: 32319040
[TBL] [Abstract][Full Text] [Related]
18. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies.
Boglione-Kerrien C; Picard S; Tron C; Nimubona S; Gangneux JP; Lalanne S; Lemaitre F; Bellissant E; Verdier MC; Petitcollin A
J Cancer Res Clin Oncol; 2018 Jan; 144(1):127-134. PubMed ID: 28932906
[TBL] [Abstract][Full Text] [Related]
19. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.
Krishna G; Ma L; Martinho M; O'Mara E
Antimicrob Agents Chemother; 2012 Aug; 56(8):4196-201. PubMed ID: 22615291
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Pharmacodynamics of Posaconazole.
Chen L; Krekels EHJ; Verweij PE; Buil JB; Knibbe CAJ; Brüggemann RJM
Drugs; 2020 May; 80(7):671-695. PubMed ID: 32323222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
